Table 1.
Fetal outcome and patient characteristics and medications prior to pregnancy
| n = 108 | |
|---|---|
| Fetal outcome | |
| Live birth, n (%) | 83 (76.9) |
| Full-term birth, n (%) | 56 (51.9) |
| Preterm birth, n (%) | 27 (25.0) |
| Miscarriage, n (%) | 11 (10.2) |
| Fetal loss, n (%) | 3 (2.8) |
| Elective abortion, n (%) | 11 (10.2) |
| Age, years old | 33 (30 - 36) |
| SLE duration, years | 8 (4 - 13) |
| History of lupus nephritis, n (%) | 29 (26.9) |
| SLEDAI, score | 0 (0 - 4) |
| Past use of steroid pulse therapy, n (%) | 27 (25.0) |
| Past use of IVCY, n (%) | 14 (13.0) |
| Prednisolone, n (%) | 91 (84.3) |
| Prednisolone dose, mg/day | 10 (5 - 12) |
| Azathioprine, n (%) | 23 (21.3) |
| Tacrolimus, n (%) | 49 (45.3) |
| HCQ, n (%) | 11 (10.2) |
| Serum C3 level, mg/dL | 81 (74 - 92) |
| Positive Anti-ds-DNA Ab, n (%) | 73 (67.6) |
| Anti-dsDNA Ab, IU/ml | 5.1 (2.5 - 8.4) |
| Positive anti-Ro/SS-A Ab, n (%) | 38 (35.2) |
| Positive LA or anti-aCL-IgG Ab or anti-β2GP1 Ab | 46 (43) |
| Positive anti-RNP Ab, n (%) | 35 (32.4) |
| Positive anti-Sm Ab, n (%) | 9 (8.3) |
Data are presented as median value (interquartile range) or number of patients
Laboratory markers were evaluated in all patients. SLE systemic lupus erythematosus, SLEDAI SLE Disease Activity Index, IVCY intravenous cyclophosphamide therapy, HCQ hydroxychloroquine, C3 complement 3, anti-dsDNA Ab anti-double-stranded DNA antibodies, anti-Ro/SS-Ab anti-Ro/SSA antibodies, LA lupus anticoagulant, aCL anticardiolipin, Β2Gp1 anti-β2-glycoprotein 1